Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Bachem, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Nitto Avecia, all published on March 24, 2026.
1 verified story tracked
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Bachem, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Nitto Avecia, all published on March 24, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nitto Avecia. Shared-story counts are live from our verified record — not editorial picks.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
